Treatment of chronic hepatitis B: Evolution over two decades

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue SUPPL. 1, 2011, Pages 138-143

  Yuen, Man Fung ^a   Lai, Ching Lung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Antiviral agents; Chronic hepatitis B; HBV DNA; Nucleoside analogs; Treatment

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; PEGINTERFERON ALPHA; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; VIRUS DNA;

ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CANCER RISK; CONTROLLED STUDY; DNA DETERMINATION; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LONG TERM CARE; MIXED INFECTION; NEPHROTOXICITY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SEROCONVERSION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRUS DETECTION; VIRUS INHIBITION; VIRUS MUTATION; VIRUS RESISTANCE;

EID: 78650780786     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06545.x     Document Type: Review

References (61)

1. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003; 362: 2089-94.
2. Wong VW, Chan HL. Severe acute exacerbation of chronic hepatitis B: a unique presentation of a common disease. J. Gastroenterol. Hepatol. 2009; 24: 1179-86.
3. Yuen MF, Hou JL, Chutaputti A; Asia Pacific Working Party on Prevention of Hepatocellular Carcinoma. Hepatocellular carcinoma in the Asia pacific region. J. Gastroenterol. Hepatol. 2009; 24: 346-53.
4. Lim SG, Mohammed R, Yuen MF, Kao JH. Prevention of hepatocellular carcinoma in hepatitis B virus infection. J. Gastroenterol. Hepatol. 2009; 24: 1352-7.
5. Chen DS. Toward elimination and eradication of hepatitis B. J. Gastroenterol. Hepatol. 2010; 25: 19-25.
6. Dianzani F. Biological basis for the clinical use of interferon. Gut 1993; 34 (Suppl.): S74-6.
7. Hoofnagle JH, Peters M, Mullen KD et al. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology 1988; 95: 1318-25.
8. Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1997; 26: 1338-42.
9. International Interferon-alpha Hepatocellular Carcinoma Study Group. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998; 351: 1535-9.
10. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29: 971-5.
11. Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, Lai CL. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001; 34: 139-45.
12. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J. Hepatol. 2001; 34: 306-13.
13. Lin SM, Yu ML, Lee CM et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J. Hepatol. 2007; 46: 45-52.
14. Yuen MF, Yuan HJ, Wong DK et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 2005; 54: 1610-14.
15. Tong MJ, Hsien C, Hsu L, Sun HE, Blatt LM. Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States. Hepatology 2008; 48: 1070-8.
16. Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
17. Iloeje UH, Yang HI, Su J et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-86.
18. Yuen MF, Tanaka Y, Fong DY et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J. Hepatol. 2009; 50: 80-8.
19. Yuan HJ, Yuen MF, Ka-Ho Wong D, Sablon E, Lai CL. The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B. J. Viral Hepat. 2005; 12: 373-9.
20. Fung J, Yuen MF, Yuen JC, Wong DK, Lai CL. Low serum HBV DNA levels and development of hepatocellular carcinoma in patients with chronic hepatitis B: a case-control study. Aliment. Pharmacol. Ther. 2007; 26: 377-82.
21. Lai CL, Yuen MF. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann. Intern. Med. 2007; 147: 58-61.
22. Frenette CT, Gish RG. To "be" or not to "be": that is the question. Am. J. Gastroenterol. 2009; 104: 1948-52.
23. Yuen MF, Wong DK, Fung J et al. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008; 135: 1192-9.
24. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J. Hepatol. 2009; 50: 227-42.
25. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 1-36.
26. Liaw YF, Leung N, Kao JH et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol. Int. 2008; 2: 263-83.
27. Keeffe EB, Dieterich DT, Han SH et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin. Gastroenterol. Hepatol. 2008; 6: 1315-41.
28. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. 1998; 339: 61-8.
29. Yuen MF, Seto WK, Chow DH et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir. Ther. 2007; 12: 1295-303.
30. Yuen MF, Fung J, Wong DK, Lai CL. Prevention and management of drug resistance for antihepatitis B treatment. Lancet Infect. Dis. 2009; 9: 256-64.
31. Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004; 351: 1521-31.
32. Matsumoto A, Tanaka E, Rokuhara A et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. Hepatol. Res. 2005; 32: 173-84.
33. Eun JR, Jang BI, Kim TN, Lee HJ, Lee KS. The effect of lamivudine on preventing hepatocellular carcinoma in chronic hepatitis B: a retrospective study of 2518 patients. Hepatology 2006; 44 (Suppl. 1): 550A.
34. Lai CL, Yuen MF. Chronic hepatitis B-new goals, new treatment. N. Engl. J. Med. 2008; 359: 2488-91.
35. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-51.
36. Zoulim F. Assessing hepatitis B virus resistance in vitro and molecular mechanisms of nucleoside resistance. Semin. Liver Dis. 2002; 22 (Suppl. 1): 23-31.
37. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45: 307-13.
38. Fung J, Lai CL, Yuen JC et al. Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population. Antivir. Ther. 2007; 12: 41-6.
39. Lampertico P, Viganò M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005; 42: 1414-19.
40. Lampertico P, Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133: 1445-51.
41. Marcellin P, Bonino F, Lau GK et al. Peginterferon alfa-2a in HBeAg-negative Chronic Hepatitis B Study Group. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009; 136: 2169-79.
42. Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2006; 354: 1001-10.
43. Lai CL, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2006; 354: 1011-20.
44. Seto WK, Lai CL, Fung J, Yuen J, Wong DKH, Yuen MF. A three-year study on viral suppression and resistance profile for treatment-naive CHB patients receiving continuous entecavir treatment. Hepatol. Int. 2010; 4: 58.
45. Chang TT, Lai CL, Kew Yoon S et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422-30.
46. Langley DR, Walsh AW, Baldick CJ et al. Inhibition of hepatitis B virus polymerase by entecavir. J. Virol. 2007; 81: 3992-4001.
47. Tenney DJ, Rose RE, Baldick CJ et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-14.
48. Suzuki Y, Suzuki F, Kawamura Y et al. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance? J. Gastroenterol. Hepatol. 2009; 24: 429-35.
49. Karino Y, Toyota J, Kumada H et al. Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B. Hepatol. Int. 2010; 4: 414-22.
50. Gish RG, Chang TT, Lai CL et al. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. J. Viral. Hepat. 2010; 17: 16-22.
51. Lai CL, Gane E, Liaw YF et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 2007; 357: 2576-88.
52. Liaw YF, Gane E, Leung N et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-95.
53. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34: (4 Pt 1) 785-91.
54. Zeuzem S, Gane E, Liaw YF et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J. Hepatol. 2009; 51: 11-20.
55. Yuen MF, Fung J, Seto WK, Wong DK, Yuen JC, Lai CL. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy. Antivir. Ther. 2009; 14: 679-85.
56. Snow-Lampart A, Chappell BJ, Curtis M et al. Resistance surveillance for up to 144 weeks in HBeAg-positive and HBeAg-nagative hepatitis B patients treated with tenofovir DF showed no relationship between virologic breakthrough and emergence of genotypic changes in HBV polymerase. Hepatology 2009; 50 (Suppl.): 532A.
57. van Bömmel F, de Man RA, Wedemeyer H et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010; 51: 73-80.
58. Yuen MF, Kim J, Kim CR et al. A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B. Antivir. Ther. 2006; 11: 977-83.
59. Yuen MF, Han KH, Um SH et al. Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease. Hepatology 2010; 51: 767-76.
60. Locarnini SA, Yuen L. Molecular genesis of drug-resistant and vaccine-escape HBV mutants. Antivir. Ther. 2010; 15: (3 Pt B) 451-61.
61. Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment. Pharmacol. Ther. 2008; 28: 1067-77.